A novel medication approach to treating obstructive sleep apnoea

Keith Burgess^{1

2

3}

Affiliations

Keith Burgess. J Physiol. 2025 May.

. 2025 May;603(10):2899-2900.

doi: 10.1113/JP288922. Epub 2025 May 22.

Keith Burgess^{1

2

3}

No abstract available

Keywords: OSA treatment; airway collapsibility; loop gain; potassium channel openner.

Conflict of interest statement

No competing interests declared.

1. Burgess, K. R. (2012). New insights from the measurement of loop gain in obstructive sleep apnoea. The Journal of Physiology, 590(8), 1781–1782. - PMC - PubMed
1. Costi, S. , Han, M.‐H. , & Murrough, J. W. (2022). The potential of KCNQ potassium channel openers as novel antidepressants. Central Nervous System Drugs, 36(3), 207–216. - PubMed
1. Deacon, N. L. , & Catcheside, P. G. (2015). The role of high loop gain induced by intermittent hypoxia in the pathophysiology of obstructive sleep apnoea. Sleep Medicine Reviews, 22, 3–14. - PubMed
1. Hedner, J. , & Zou, D. (2018). Drug therapy in obstructive sleep apnea. Sleep Medicine Clinics, 13(2), 203–217. - PubMed
1. Thomson, L. D. J. , Landry, S. A. , Arellano, A. , Collet, J. , Huddle, S. , O'Driscoll, D. M. , Mann, D. L. , Beatty, C. , Joosten, S. A. , Hamilton, G. S. , Berger, P. J. , Cooke, I. , & Edwards, B. A. (2025). The effect of M‐current activation on controller gain and obstructive sleep apnoea severity: A randomised controlled trial using Flupirtine. The Journal of Physiology, 603(10), 3245–3260. - PMC - PubMed